TRADING 14 SA FOR MNKD and MU

[TREND1]

6/19 MannKind: Afrezza Scripts Above 300 - Can Sales Keep Climbing?

•Total scripts come in just above 300.

•Scripts have had a "see-saw" effect in the past.

•Company cash situation still unresolved.


https://seekingalpha.com/article/4082294-mannkind-afrezza-scripts-300-can-sales-keep-climbing?auth_param=1vat:1ckfh3l:64a3d2b52e3c083ecf054ec5e203cfe3&uprof=51

[TREND1]

ism data from WHS
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132250685

[TREND1]

Shorts lose battles, but rarely lose the war

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132249530

[TREND1]

Largest 50 companies by market cap

http://www.dogsofthedow.com/largest-companies-by-market-cap.htm

[TREND1]

6/14 Cash flow positive by Q4 2017

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132189674

[TREND1]

6/13 MannKind - Afrezza Adverse Events Data Q1 2017


https://seekingalpha.com/instablog/175233-spencer-osborne/4999115-mannkind-afrezza-adverse-events-data-q1-2017?uprof=51&isDirectRoadblock=false

[TREND1]

6/13 MannKind Scripts Not Helping Cash Situation


•Afrezza scripts remain below 300.

•MannKind has only 4 weeks to figure out $10 million payment to Deerfield.

•Company is saying the right things, but the details still lacking



https://seekingalpha.com/article/4081146-mannkind-scripts-helping-cash-situation?auth_param=1vat:1ck092f:079d14ec598054438e5a5d728bc91cc1&uprof=51

[TREND1]

6/8 I do not see AFREZZA drop out rate falling very much.
AFREZZA will cause a MNKD BK.
It is just a mater of time. IMHO.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132015970

[TREND1]

6/6 The rejection rate for AFREZZA is 95.5 per 100 for the last 10 weeks


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131940704

[TREND1]

5/30/17 Hypi sees a buy out by AMGN

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131759835

[TREND1]

6/4/17 tx_farmer You say $10 by 12/4/17


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131898834&txt2find=$10

[TREND1]

6/6/17 Hypi says $7 or $8 by 12/31/17

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=131962845

[TREND1]

6/5 MannKind - Afrezza Scripts Dip As Company Announces Deal For Brazil


•Afrezza scripts are below 300 per week.

•MannKind announces deal for Brazil.

•Cash remains critical concern.


https://seekingalpha.com/article/4078986-mannkind-afrezza-scripts-dip-company-announces-deal-brazil?auth_param=1vat:1cjbs9d:5b6496efec36dabb924fa5d8fb91a871&uprof=51

[TREND1]

DATA

[TREND1]

5/31 MannKind Promotes New CEO - Will Strategy Shift Happen?

CEO Matthew Pfeffer leaving company.

•CCO Mike Castagna promoted to CEO.

•Rose Alinaya will be acting CFO.



https://seekingalpha.com/article/4077610-mannkind-promotes-new-ceo-will-strategy-shift-happen?auth_param=1vat:1citgk5:93bcae423c7b0903ac22db5ce408cc0a&uprof=51

[TREND1]

5/30 MannKind: Scripts Dip, But Stock Moves On Technicals

•Afrezza scripts dip below 300 again.

•Cash situation remains paramount.

•MannKind Stock now at higher end of technical move.



https://seekingalpha.com/article/4077344-mannkind-scripts-dip-stock-moves-technicals?auth_param=1vat:1ciqtss:e397e99d94b906e6bb59f330553e96f0&uprof=51

[TREND1]

5/23 MannKind Contract With Amphastar

CONFIDENTIAL TREATMENT REQUESTED



https://seekingalpha.com/instablog/175233-spencer-osborne/4992182-mannkind-contract-amphastar?uprof=51&isDirectRoadblock=false

[TREND1]

5/21 MannKind - Afrezza Adverse Events Since Launch

I try to help readers by giving assessing data I collect and making components of that data available. Adverse events data is time consuming to collect, and this data has value as it is not widely distributed in a very user friendly way. Despite my better judgment, I will provide the adverse events data for free from product launch through Q4 of 2016. In the future, if a reader desires this data, I can point out to you where to buy it, or where you can obtain the raw data so that you can build the tables yourselves.

A few items of note:
•There have been hospitalizations
•There have been two deaths
•Many issues seem to indicate that the drug is not effective
•Coughs are common
•Lack of glucose control is common
•Ever since MannKind took over in Q3 of 2016, the event reporting has decreased. This could be that MannKind views what is reportable differently than other big pharma companies. MannKind is not very experienced in running a pharma company.



https://seekingalpha.com/instablog/175233-spencer-osborne/4991461-mannkind-afrezza-adverse-events-since-launch?uprof=51&isDirectRoadblock=false

[TREND1]

5/19 Afrezza: What Is Possible Vs. What Is Probable

•Afrezza scripts pass above 300 for the week ending May 12.

•At annual meeting MannKind speaks to Afrezza without a prescription.

•Cash remains critical issue with this company.


https://seekingalpha.com/article/4074826-mannkind-afrezza-scripts-rise-management-offers-investors-new-carrot?auth_param=1vat:1chug6f:799d8319c7ec31623d8013845d4e89ab&uprof=51#alt3

[TREND1]

5/18 Reading MannKind's SEC Documents Would Help Investors Preserve Their Capital

•Understanding the difference between public statements versus SEC documents that require more relevant and accurate information.

•Seeking to change how you score a game,during the middle of the game, is a good indicator you are losing the game.

•Twenty plus years of promises about expanding the TI platform has resulted in failure to deliver on the promises.



https://seekingalpha.com/article/4074453-reading-mannkinds-sec-documents-help-investors-preserve-capital?auth_param=1vat:1chrojg:055062b6cc07e9fc89d66f39a70b7510&uprof=51

[TREND1]

5/12 MannKind - Afrezza Script Sales Stable But Low


•Afrezza weekly sales remain below 300 per week.

•Refill data remains primary concern.

•Company already conducted quarterly call and annual meeting is a week away.




https://seekingalpha.com/article/4072692-mannkind-afrezza-script-sales-stable-low?auth_param=1vat:1chbs0r:4f26dcfe830de0fbea5afddb0182c19f&uprof=51

[TREND1]

5/12 Mannkind Q1: Nothing But Losses

•The first quarter had losses of $16.3 million.

•The company made more money selling bulk insulin than their inhalable drug Afrezza.

•With no improvement in sales, I don't know how MannKind can stem its losses from continuing.



https://seekingalpha.com/article/4072614-mannkind-corp-nothing-losses?auth_param=1vat:1chbheb:1f209c2fbcc6e4f8348f309ff84c9019&uprof=51#alt3

[TREND1]

5/11 MannKind Reports Q1 Loss - What Investors Need To Know


•MannKind reported a net loss of $16.3 million.

•MannKind finished Q1 with $47.9 million.

•Afrezza sales averaged about $375 per script.


https://seekingalpha.com/article/4072216-mannkind-reports-q1-loss-investors-need-know?auth_param=1vat:1ch945u:4e3ebe71f36934abb9f4c471c0d546d2&uprof=51

[TREND1]

5/11 MannKind Q1 revenue disappoints, shares down 15%


•MannKind (MNKD -14.7%) Q1 results ($M): Revenue: 3.0, Commercial Product Sales: 1.2, Bulk Insulin Sales: 1.8.

•Net Loss: (16.3) (+34.5%); Loss/Share: (0.17) (+41.4%).

•FDA decision on Afrezza labeling update expected by September 30.

•Investors are expected some daylight regarding Afrezza sales. Consensus view for Q2 and full-year are $2.8M and $28M, respectively.





https://seekingalpha.com/news/3266525-mannkind-q1-revenue-disappoints-shares-15-percent?uprof=51#email_link

[TREND1]

5/10 MannKind's (MNKD) CEO Matthew Pfeffer on Q1 2017 Results - Earnings Call Transcript



https://seekingalpha.com/article/4072017-mannkinds-mnkd-ceo-matthew-pfeffer-q1-2017-results-earnings-call-transcript?auth_param=1vat:1ch7mh7:5f1770e8745ebeaf0c4311262278c653&uprof=51

[TREND1]

5/8 MannKind Making Moves, Could Gain Nasdaq Compliance With Strong Close


•Stock had traded outside Nasdaq compliance for 10 days.

•A closing bid price above $1 per share will reset the compliance clock.

•The earnings call is two days away. Will the fundamental story change?



https://seekingalpha.com/article/4070802-mannkind-making-moves-gain-nasdaq-compliance-strong-close?auth_param=1vat:1ch1mv6:b5a32b1b52c69127ccdb8f5551704bbb&uprof=51

[TREND1]

5/5 MannKind: Afrezza Sales Still Low As Company Tries To Increase Outreach


•MannKind and One Drop may collaborate.

•Scripts remain below 300 per week.

•Refills remain a concern.



https://seekingalpha.com/article/4069746-mannkind-afrezza-sales-still-low-company-tries-increase-outreach?auth_param=1vat:1cgpgkl:f37d2f963407edaf90204739b37a7857&uprof=51

[TREND1]

5/2 MannKind Hopes To Reverse Fortunes With Television Show


•"Reversed" will air on Discovery Life beginning in July.

•"Reversed" is a reality show about diabetes.

•MannKind is the sole sponsor of the show.



https://seekingalpha.com/article/4068022-mannkind-hopes-reverse-fortunes-television-show?auth_param=1vat:1cghqo8:5e7a3e8bf51bd395aecbdaaf5adf1000&uprof=51

[TREND1]

5/1 MannKind: Mann Trust Executors Are Selling Massive Numbers Of Common Shares


MannKind is trading at a historical low price per share.

•Deerfield has converted debt equity into common shares that now can be sold into the market.

•As of today(May 1, 2017) it appears that MannKind no longer has a lease for their principal executive office.




https://seekingalpha.com/article/4067549-mannkind-mann-trust-executors-selling-massive-numbers-common-shares?auth_param=1vat:1cgf139:b0522cd4b576deea401788aa1143b6cb&uprof=51

[TREND1]

4/28 MannKind - Afrezza Scripts Dip Again As Investor Frustration Rises

•Afrezza sales for week ending 4/21 were just below 240.

•Sales over the last 8 weeks have seen minimal growth.

•Investor frustration on the rise as stock is below $1 again.




https://seekingalpha.com/article/4066772-mannkind-afrezza-scripts-dip-investor-frustration-rises?auth_param=1vat:1cg6urm:7b50dffc59c75e7f83fb8c64577b3b14&uprof=51

[TREND1]

4/25 MannKind May Not Go Bankrupt, But...

•MannKind is in a cash crunch and lacks leverage.

•There are many ways to stave off bankruptcy.

•Traders who are jockeying for position now could have upside.



https://seekingalpha.com/article/4065089-mannkind-may-go-bankrupt?auth_param=1vat:1cfv8k2:b029fe77779e7ff8ff889d9102dc0af7&uprof=51

[TREND1]

4/25 MannKind Corporation Needs A Merger

David Butler



•MannKind's financial situation has failed to improve given the amount of time the company has had.

•At the rate that it burns money, the only glimmer I see for shareholders would be getting bought out.

•If their Q1 doesn't show sales growth, it could be a tough sell to potential buyers.



https://seekingalpha.com/article/4064883-mannkind-corporation-needs-merger?app=1&auth_param=1vat:1cfuh98:4870f66196271e943a76d782ee5a15d4&uprof=51

[TREND1]

4/21 MannKind Under A Buck - New Script Numbers Remain Below 300

•Weekly scripts remain below 300.

•MannKind stock dips below $1.00.

•Stock is currently not in compliance with NASDAQ listing requirements.


https://seekingalpha.com/article/4064186-mannkind-buck-new-script-numbers-remain-300?app=1&auth_param=1vat:1cfkfub:46d7461fa12a1010fc9f4b9c2ed381bf&uprof=51

[TREND1]

4/20 MannKind Renegotiates Debt With Dilution - What Does This Mean To Investors?

•MannKind uses shares to pay $6 million worth of debt.

•Deerfield becomes a 5% stakeholder.

•Cash crunch is still very real.


https://seekingalpha.com/article/4063633-mannkind-renegotiates-debt-dilution-mean-investors?app=1&auth_param=1vat:1cfgp2d:74d4b80d54adcbad25a67d734ee7481e&uprof=51

[TREND1]

4/17 MannKind - Stagnant Sales Demand That Investors Take Emotion Out Of The Equation


•Afrezza Sales for week ending April 7th were below 250 scripts.

•Cash burn continues to erode leverage.

•This is not about Afrezza, It is about whether MannKind is a good investment play.



https://seekingalpha.com/article/4062782-mannkind-stagnant-sales-demand-investors-take-emotion-equation?app=1&auth_param=1vat:1cf9qpo:ffa4a99e0fcd5bdf8a8366dfce7ac29a&uprof=51

[TREND1]

4/13 First patient in Asia implanted with Second Sight's Argus II; shares ahead 29% premarket

Apr. 13, 2017 7:27 AM ET|About: Second Sight Medical P... (EYES)|By: Douglas W. House, SA News Editor



•Second Sight Medical Products (NASDAQ:EYES) announces that the first patient in Asia, a blind 40-year old Taiwanese suffering from retinal degeneration, has been implanted with the Argus II Retinal Prosthesis System through an exclusive distribution partnership with Orient Europharma Co. Ltd. and charitable support from a Taiwan-based foundation.

•Argus II converts images captured by a miniature camera mounted on the patient's glasses into a series of tiny electrical pulses that are wirelessly transmitted to an array of electrodes implanted on the surface of the retina. The pulses stimulate the remaining viable retinal cells resulting in the perception of patterns of light. The patient regains some visual capability by learning to interpret the visual patterns.

•Shares are up 29% premarket on modest volume.




https://seekingalpha.com/news/3256986-first-patient-asia-implanted-second-sights-argus-ii-shares-ahead-29-percent-premarket?app=1&uprof=51#email_link

[TREND1]

4/10 MannKind Closes Out Worst Full Quarter Of Afrezza Sales As Management Gets Golden Parachutes

•Afrezza Sales see spike but remain below 300 weekly scripts.

•Q1 of 2017 is the worst full quarter sales in 2 years for Afrezza.

•Management seeks a golden parachute in the form of Change of Control Agreements.



https://seekingalpha.com/article/4061406-mannkind-closes-worst-full-quarter-afrezza-sales-management-gets-golden-parachutes?app=1&auth_param=1vat:1cen03s:7641fec549d1bd0ca63ec4aad720dc80&uprof=51

[TREND1]

4/4 Flexion Therapeutics issues two new patents to strengthen intellectual property protection for Zilretta

•Flexion Therapeutics (NASDAQ:FLXN) announces the U.S. Patent and Trademark Office has issued two new patents covering the company’s lead investigational product candidate Zilretta (FX006).

•The first patent includes the treatment of a variety of indications associated with pain and inflammation. The second covers methods of manufacturing injectable extended-release microparticles that combine triamcinolone acetonide and PLGA.

•Zilretta’s composition of matter, method of use and method of manufacturing patents provide protection into 2031.

•Zilretta is being investigated as the first intra-articular, extended-release treatment for patients with osteoarthritis (OA)-related knee pain.


•Now read: 3 Possible Biotech Takeout Targets In The Second Quarter




https://seekingalpha.com/news/3255379-flexion-therapeutics-issues-two-new-patents-strengthen-intellectual-property-protection?app=1&uprof=51#email_link

[TREND1]

4/3 MannKind: Afrezza Scripts Remain Underwhelming

•Afrezza sales remain well below 300 scripts per week.

•MannKind cash continues to dwindle.

•Some form of capital raise needs to happen in Q2


https://seekingalpha.com/article/4059918-mannkind-afrezza-scripts-remain-underwhelming?app=1&auth_param=1vat:1ce58tq:a210adf86817aeba85b37d2ab8438d1a&uprof=51

[TREND1]

MannKind Corp.: Bleeding Out And On Its Deathbed

Stephen Fortin

•The non-inferiority of Afrezza to traditional insulin regimens in questionable.

•MNKD has been ineffective in marketing to physicians and the diabetic population alike.

•Script counts are declining, but MNKD needs an 85-fold increase in scripts just to break even.

•Further dilution is coming, and investors should steer clear of the stock.


https://seekingalpha.com/article/4059186-mannkind-corp-bleeding-deathbed?app=1&auth_param=1vat:1cdqf89:05aa6a00d7b88e6106b01c111f6c0bc9&uprof=51

[TREND1]

MannKind: Afrezza Sales Remain Low As Q1 Comes To A Close


•Afrezza sales for the week ending March 17 were just under 260 scripts.

•Sales need to be substantially higher to impress the street and/or potential partners.

•Trend lines are simply not favorable.




https://seekingalpha.com/article/4058138-mannkind-afrezza-sales-remain-low-q1-comes-close?app=1&auth_param=1vat:1cdi6op:8428040722f5dc8cebbe13c764e14165&uprof=51

[TREND1]

Bank Of America: Buy The Dip

Mar. 21, 2017 3:44 PM ET
•As banks fall, and the bears salivate, investors have something to think about.

•This had to happen at some point. How is BAC placed?

•Banks aren't forecasting aggressive rate hikes themselves. Focus on the core situation and see through oil and the 10 year action today


http://seekingalpha.com/article/4056911-bank-america-get-ready-buy?app=1&auth_param=1vat:1cd30l3:139e876f38885cbb7eba0089915029dc&uprof=51#alt3

[TREND1]

What MannKind's Cash Situation Truly Looks Like

Mar. 20, 2017 2:40 PM ET
(2,404 followers)

•Company has substantial debt payments due in the coming months.

•Company cash burn rate is still about the same as I have been projecting.

•Covenants make issue more challenging.




http://seekingalpha.com/article/4056599-mannkinds-cash-concern-investors?app=1&auth_param=1vat:1cd08gt:850d60af96b6679a4ac5bbb9778fc63a&uprof=51#alt3

[TREND1]

3/20 MannKind Beats Street With Settlement Revenue; Script Sales Still Low

Mar. 20, 2017 8:29 AM ET

•MannKind shows profit thanks to one-time event.

•Afrezza revenue in 2016 was under $2 million.

•MannKind's cash situation remains a chief concern.




http://seekingalpha.com/article/4056456-mannkind-beats-street-settlement-revenue-script-sales-still-low?app=1&auth_param=1vat:1ccviq9:40ef90f90669c3f72a7b763925e90bc2&uprof=51

[TREND1]

3/16 MannKind's (MNKD) CEO Matthew Pfeffer on Q4 2016 Results - Earnings Call Transcript

http://seekingalpha.com/article/4056011-mannkinds-mnkd-ceo-matthew-pfeffer-q4-2016-results-earnings-call-transcript?app=1&auth_param=1vat:1ccmkl6:b68dd5fa7883ad41eb7ef0d20dfd2b95&uprof=51

[TREND1]

3/14

MannKind's (MNKD) CEO Matt Pfeffer Presents At 29th Annual ROTH Conference (Transcript)

Mar. 14, 2017 12:54 AM ET

MannKind Corporation (NASDAQ:MNKD)

29th Annual ROTH Conference Call

March 13, 2017 8:00 PM ET



http://seekingalpha.com/article/4054768-mannkinds-mnkd-ceo-matt-pfeffer-presents-29th-annual-roth-conference-transcript?app=1&auth_param=1vat:1ccetro:0023290d5855152d48e102bdb5c5a1ca&uprof=51

[TREND1]

Bank Of America: Historical Indicators Of A Correction

Mar. 10, 2017 3:38 AM ET

•As bank stocks surge, so too does the risk of a correction. Bank of America is up over 100% since June of last year.

•Now is the time to map out how a correction might play out using momentum indicators and historical analysis.

•History has shown that lower highs in the Relative Strength Index, correspond to choppy trading and an increase in the number of pullbacks for Bank of America.


http://seekingalpha.com/article/4054033-bank-america-historical-indicators-correction

[TREND1]

MannKind Needs To Boost Script Sales - Will A Television Show Help?


Mar. 10, 2017 5:05 PM ET
Spencer Osborne

•Sales of Afrezza remain much lower than needed.

•Company will participate in a television show launching this summer.

•Cash issues remain critical.




http://seekingalpha.com/article/4054283-mannkind-needs-boost-script-sales-will-television-show-help?app=1&auth_param=1vat:1cc68ql:015534b333e3a8397d466db6148b9e7d&uprof=51

[TREND1]

http://seekingalpha.com/news/3248945-vermillions-aspira-labs-secures-state-provider-status-california-medicaid-shares-shares-ahead

[TREND1]

MannKind - Afrezza Sales Struggle As February Comes To A Close

Mar. 6, 2017 9:11 AM ET

Spencer Osborne

•Afrezza sales dip to 225 scripts for week ending February24th.

•Afrezza is now on its 3rd sales force in two years.

•Company conducted reverse split but financial concerns remain



http://seekingalpha.com/article/4052288-mannkind-afrezza-sales-struggle-february-comes-close?app=1&auth_param=1vat:1cbqrhd:e7824bc5eacd85c89d781b4a03ff10bd&uprof=51